secwatch.observer — SEC 8-K summary
======================================

Issuer:     Altimmune, Inc. (ALT)
CIK:        0001326190
Form:       8-K
Filed at:   2023-08-10T23:59:59+00:00
Accession:  0001326190-23-000033
Event type: earnings
Sentiment:  neutral
Materiality: 0.50
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Altimmune Q2 net loss $16.1M; pemvidutide obesity trial data expected Q4 2023
-----------------------------------------------------------------------------

- Net loss of $16.1M ($0.32/share) vs $20.1M ($0.42/share) in Q2 2022.
- Cash, equivalents & short-term investments totaled $160.0M as of June 30, 2023.
- R&D expenses $13.3M, G&A $4.8M for the quarter.
- Top-line 48-week MOMENTUM Phase 2 obesity trial results expected Q4 2023.
- Enrollment commenced in IMPACT Phase 2b NASH trial; top-line data expected Q1 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1326190/000132619023000033/0001326190-23-000033-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1326190/000132619023000033/alt-20230810x8k.htm
  HTML page:      https://secwatch.observer/filing/0001326190-23-000033

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer